NASDAQ:MEDP Medpace (MEDP) Stock Forecast, Price & News $242.15 -2.55 (-1.04%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$242.15▼$248.2350-Day Range$240.81▼$281.6752-Week Range$146.05▼$282.73Volume182,143 shsAverage Volume335,691 shsMarket Capitalization$7.40 billionP/E Ratio28.93Dividend YieldN/APrice Target$264.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Medpace MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside9.2% Upside$264.33 Price TargetShort InterestHealthy4.00% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.10Based on 12 Articles This WeekInsider TradingSelling Shares$93.18 M Sold Last QuarterProj. Earnings Growth16.09%From $8.39 to $9.74 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector112th out of 964 stocksCommercial Physical Research Industry4th out of 14 stocks 1.2 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $264.33, Medpace has a forecasted upside of 9.2% from its current price of $242.15.Amount of Analyst CoverageMedpace has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.00% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently decreased by 5.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.8 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Medpace this week, compared to 4 articles on an average week.Search Interest2 people have searched for MEDP on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Medpace to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,178,274.00 in company stock.Percentage Held by Insiders25.70% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 16.09% in the coming year, from $8.39 to $9.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 28.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 28.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.00.Price to Book Value per Share RatioMedpace has a P/B Ratio of 19.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medpace (NASDAQ:MEDP) StockMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comMedpace Holdings, Inc. to Report Third Quarter 2023 Financial Results on October 23, 2023September 23, 2023 | americanbankingnews.comMedpace Investors, Llc Sells 65,653 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) StockSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 23, 2023 | americanbankingnews.comAugust J. Troendle Sells 61,655 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) StockSeptember 23, 2023 | americanbankingnews.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells $35,671,831.14 in StockSeptember 22, 2023 | americanbankingnews.comInsider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells 137,379 Shares of StockSeptember 22, 2023 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Major Shareholder Sells $14,668,062.60 in StockSeptember 19, 2023 | finance.yahoo.comUnveiling Medpace Holdings (MEDP)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 12, 2023 | bizjournals.comFive Things: Aglamesis rebrands, Medpace's headquarters expansion growsSeptember 11, 2023 | bizjournals.comMedpace's massive Madisonville expansion expected to top $230M, add 2,700 seatsSeptember 9, 2023 | msn.comMedpace: A Great Anchor For A Long-Term PortfolioSeptember 7, 2023 | bizjournals.comCincinnati among top metros in Site Selection's new ranking of public, private investmentSeptember 1, 2023 | finance.yahoo.comMedpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?August 30, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Medpace, HealthEquity and Surgery PartnersAugust 29, 2023 | finance.yahoo.com3 Top Stocks Exhibiting Superb Earnings GrowthAugust 23, 2023 | finance.yahoo.comReasons for the Outperformance of Medpace Holdings (MEDP)August 21, 2023 | msn.comMedpace (MEDP) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAugust 18, 2023 | msn.comCincinnati road closures Saturday for Black Family Reunion Parade, Medpace 5KAugust 15, 2023 | fool.comMedpace (NASDAQ: MEDP)August 10, 2023 | seekingalpha.comMedpace Holdings, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 5, 2023 | fool.comChecking In on Medpace, Autoliv, and 401(k) PlansJuly 26, 2023 | finance.yahoo.comMedpace Holdings, Inc.: Medpace Earnings: Healthy Outsourcing Demand Drives Growth and Supports Narrow MoatJuly 26, 2023 | markets.businessinsider.comMedpace Outperforms Q2 Expectations: Analyst Says High Expectations, Softer Margins Will Likely Temper EnthusiasmJuly 26, 2023 | finance.yahoo.comQ2 2023 Medpace Holdings Inc Earnings CallJuly 24, 2023 | washingtonpost.comMedpace: Q2 Earnings SnapshotJuly 24, 2023 | finance.yahoo.comMedpace (MEDP) Surpasses Q2 Earnings and Revenue EstimatesSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Company Calendar Last Earnings7/24/2023Today9/26/2023Next Earnings (Estimated)10/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$264.33 High Stock Price Forecast$273.00 Low Stock Price Forecast$250.00 Forecasted Upside/Downside+8.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$8.37 Trailing P/E Ratio29.09 Forward P/E Ratio29.02 P/E GrowthN/ANet Income$245.37 million Net Margins16.06% Pretax Margin18.97% Return on Equity72.88% Return on Assets19.60% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual Sales$1.46 billion Price / Sales5.10 Cash Flow$8.62 per share Price / Cash Flow28.26 Book Value$12.42 per share Price / Book19.60Miscellaneous Outstanding Shares30,560,000Free Float22,708,000Market Cap$7.44 billion OptionableOptionable Beta1.37 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 67)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 49)CPA, Pres Comp: $876.92kMr. Kevin M. Brady (Age 48)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 60)MA, Exec. VP of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 54)Chief Compliance Officer, Gen. Counsel & Corp. Sec. Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVP of Bus. Devel. & MarketingJohn T. Wynne MBASr. VP of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 62)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsSyneos HealthNASDAQ:SYNHIncyteNASDAQ:INCYICON PublicNASDAQ:ICLRChemedNYSE:CHEShockwave MedicalNASDAQ:SWAVView All CompetitorsInsiders & InstitutionsAugust J TroendleSold 61,655 sharesTotal: $15.06 M ($244.27/share)Medpace Investors, LlcSold 65,653 sharesTotal: $16.77 M ($255.48/share)August J TroendleSold 137,379 sharesTotal: $35.67 M ($259.66/share)Medpace Investors, LlcSold 53,385 sharesTotal: $14.67 M ($274.76/share)Portside Wealth Group LLCBought 1,137 shares on 9/1/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions MEDP Stock - Frequently Asked Questions Should I buy or sell Medpace stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price forecast for 2023? 3 Wall Street analysts have issued 1 year price objectives for Medpace's stock. Their MEDP share price forecasts range from $250.00 to $273.00. On average, they anticipate the company's stock price to reach $264.33 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2023? Medpace's stock was trading at $212.41 at the start of the year. Since then, MEDP stock has increased by 14.6% and is now trading at $243.49. View the best growth stocks for 2023 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, October 23rd 2023. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, July, 24th. The company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.90 by $0.03. The company had revenue of $460.90 million for the quarter, compared to analysts' expectations of $433.75 million. Medpace had a trailing twelve-month return on equity of 72.88% and a net margin of 16.06%. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2023 earnings guidance on Monday, July, 24th. The company provided EPS guidance of $8.04-$8.50 for the period, compared to the consensus estimate of $8.23. The company issued revenue guidance of $1.84 billion-$1.88 billion, compared to the consensus revenue estimate of $1.78 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." Who are Medpace's major shareholders? Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.11%), Wasatch Advisors LP (5.13%), State Street Corp (2.20%), Riverbridge Partners LLC (2.14%), Boston Trust Walden Corp (1.80%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $243.49. How much money does Medpace make? Medpace (NASDAQ:MEDP) has a market capitalization of $7.44 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $8.37 on an earnings per share basis. How many employees does Medpace have? The company employs 5,200 workers across the globe. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444. This page (NASDAQ:MEDP) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.